The overseas market of well-known pharmaceutical enterprises increased steadily, and the two major products obtained the approval of foreign access

[pharmaceutical network industry trends 】On November 26, Taiji Group announced that its holding subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory Co., Ltd (hereinafter referred to as Fuling pharmaceutical factory), had recently received the access approval issued by the health and over-the-counter medicine department of Pakistan drug administration, approving that the company's products Huoxiang Zhengqi oral liquid and Jizhi syrup can be used in the Islamic Republic of Pakistan (hereinafter referred to as "the Islamic Republic of Pakistan") : Pakistan)   Taiji Group Huoxiang Zhengqi oral liquid, as the first low-cost drug with a unified sales price of one million national sales terminals in the domestic pharmaceutical market, has been widely used in the image of heatstroke prevention and gastroenteric cold medicine through unremitting consumer experience and education, as well as millions of real world studies conducted for two years The leading position in the domestic market is very high Hard to shake According to some data, its market share has reached 32.12% in 2018 As of July 2019, Taiji Group Huoxiang Zhengqi oral liquid has been registered in 14 countries and regions including Russia, Canada, the United States, Singapore, Russia, etc It is planned to be marketed in at least 50 countries and regions by 2027, and become a person who will take traditional Chinese medicine to the world As an old brand in Chinese cough medicine market for many years, Jizhi syrup of Taiji Group has set a record of annual sales of 100 million bottles in 1998, which is also a syrup product rarely exported in China Its main treatment is clearing away heat and resolving phlegm, promoting lung and relieving cough It is used for cough caused by exogenous wind heat Symptoms include fever, cold, chest and diaphragm fullness, cough and sore throat; acute bronchitis, acute attack of chronic bronchitis, etc Especially in the treatment of acute bronchitis, cough after cold and acute attack of chronic bronchitis and other respiratory diseases As one of the key products of Taiji group, its sales revenue of quick syrup in 2018 was 320 million yuan including tax This time, Huoxiang Zhengqi oral liquid and Jizhi syrup won the market access approval of Pakistan, which not only indicates that Huoxiang Zhengqi oral liquid and Jizhi syrup can be sold in Pakistan, expanding the consumer population, but also brings more positive impact on Taiji Group's overseas market expansion In addition, the author noted that Taiji Group also announced on the same day that its holding subsidiary, Southwest Pharmaceutical, recently received the approval document for supplementary drug application (approval document No.: 2019b04221) issued by the State Food and drug administration The "isoniazid tablet" applied by Taiji group passed the consistency evaluation of quality and efficacy of generic drugs It is reported that isoniazid tablet is the first-line antituberculous drug recommended by who, the basic drug in the standard treatment of antituberculosis, and the class a drug in the catalogue of national basic medical insurance, industrial injury insurance and maternity insurance (2019 version) At present, 379 domestic enterprises have the production approval documents of the product, and 5 enterprises (including Southwest Pharmaceutical) have passed the consistency evaluation According to new iqvia data, in 2018, the sales volume of isoniazid tablets in China was about 94.36 million yuan Since Southwest Pharmaceutical submitted the application for conformity assessment to the State Food and Drug Administration in September 2018, Southwest Pharmaceutical has invested 4.86 million yuan in R & D of the product.